Healthcare Sector

In Vitro & In Vivo Diagnostic Substances Industry  

Data by Company within In Vitro & In Vivo Diagnostic Substances Industry

  Marketcap Revenues (TTM) Net Income (TTM) Employees
Company (Millions) (Millions) (Millions) Number
Idexx Laboratories Inc $ 40,134 $ 3,660 $ 845 10,350
Oncocyte Corporation $ 21,135 $ 6 $ -77 -
Ortho Clinical Diagnostics Holdings Plc $ 8,448 - $ 54 -
Lantheus Holdings Inc $ 4,379 $ 1,296 $ 327 1,000
Quidelortho Corp $ 2,617 $ 3,122 $ 13 -
Neogen Corporation $ 2,587 $ 918 $ -27 1,700
Intellia Therapeutics Inc $ 1,890 $ 52 $ -462 -
Celldex Therapeutics inc $ 1,866 $ 7 $ -141 -
Myriad Genetics Inc $ 1,533 $ 753 $ -263 2,700
Meridian Bioscience Inc $ 1,504 $ 339 $ 62 850
Heska Corporation $ 1,247 $ 255 $ -20 542
Mymd Pharmaceuticals Inc $ 113 - $ -5 -
Achieve Life Sciences Inc $ 97 - $ -36 -
Trinity Biotech Plc $ 63 $ 75 $ -41 569
Alpha Teknova Inc $ 60 $ 36 $ -39 -
Arca Biopharma Inc $ 47 - $ -5 -
Volitionrx Limited $ 44 $ 1 $ -35 -
Immucell Corp $ 39 $ 16 $ -6 -
Quotient Limited $ 39 $ 39 $ -136 -
Aspira Women s Health Inc $ 33 $ 9 $ -17 1,433
Lucira Health Inc $ 18 $ 212 $ -143 100
Nymox Pharmaceutical Corporation $ 18 $ 0 $ -7 -
Cardio Diagnostics Holdings Inc $ 14 $ 11 $ -8 -
Biomerica Inc $ 11 $ 5 $ -7 -
Burzynski Research Institute Inc $ 6 - $ -1 -
Navidea Biopharmaceuticals Inc $ 3 $ 1 $ -1 -
In Vitro & In Vivo Diagnostic Substances Industry $ 87,944 $ 10,805 $ -178 19,244
  Recent News from In Vitro & In Vivo Diagnostic Substances Industry
Clinical Study

Promising Developments in Chronic Inducible Urticaria Treatment: Celldex Completes Patient Enrollment in Phase 2 Barzolvolimab Study

(NEJM) reports on an important development announced by Celldex Therapeutics, Inc., regarding their clinical study of barzolvolimab, an investigational compound intended for the treatment of chronic inducible urticaria (CIndU), specifically cold urticaria (ColdU) and symptomatic dermographism (SD).According to the announcement made on April 17, 2024, the...


QuidelOrtho Corporation Investors Urged to Seek Legal Counsel Ahead of Securities Class Action Deadline

Rosen Law Firm, a renowned global investor rights law firm, has issued a press release announcing the filing of a class action lawsuit on behalf of purchasers of QuidelOrtho Corporation common stock (NASDAQ: QDEL). The lawsuit encompasses the period between February 18, 2022, and April 1, 2024 (the Class Period). Investors who have been impacted by this a...

Clinical Study

Revolutionary Myriad Genetics Study Reveals Breakthrough in Prenatal Screening for 22q11.2 Microdeletion Syndrome

A remarkable scientific study spearheaded by Myriad Genetics, Inc., a pioneering front-runner in genetic testing and precision medicine, has been recently published in Prenatal Diagnosis. This groundbreaking study illustrates the superior Positive Predictive Value (PPV) for 22q11.2 microdeletion syndrome screening via Myriad's innovative prenatal cell-fre...

Management Announcement

Biomerica Defies Odds in Expanding inFoods IBS Platform, Poised to Revolutionize Healthcare

In an era of increasing public health concerns and escalating medical expenses, Biomerica, a leading global provider of advanced diagnostic products, is making groundbreaking strides in expanding its innovative inFoods platform dedicated to managing and treating Irritable Bowel Syndrome (IBS). With a mission to transform healthcare outcomes for ...

Financing Agreement

Oncocyte Corporation Successfully Raises $15.8 Million Through Innovative Nasdaq-Compliant Private Placement

In a significant development for the rapidly evolving diagnostic industry, Oncocyte Corporation has announced the successful completion of a $15.8 million private placement of securities. Under Nasdaq regulations, the company priced these securities at-the-market (ATM), demonstrating their commitment to transparency and efficient capital raising...

Aspira Women S Health Inc

Aspira Women's Health Inc Faces Revenue Drop Amidst Financial Challenges

As a financial journalist for The , I have analyzed the recent financial results of Aspira Women's Health Inc and In Vitro and In Vivo Diagnostic Substances company. The numbers paint a picture of two companies facing different challenges in the current market environment.
Aspira Women's Health Inc has reported weakening business performance in the mo...

Cardio Diagnostics Holdings Inc

Headline: CDIO Shows Exceptional Performance with $5.31 Million Revenue Increase in Q4 2023

CDIO, or Cardio Diagnostics Holdings Inc, recently announced strong revenue improvement in the period from October to December 2023. Their revenue increased to $5.31 million, a significant boost compared to the same period the previous year. However, despite this positive growth, the company experienced a deficit per share of $-0.11.
Interestingly, CD...

Clinical Study

Advancing Treatment for Chronic Skin Diseases: The ARCA biopharma and Oruka Therapeutics Merger Agreement

The recent merger agreement between ARCA biopharma and Oruka Therapeutics has paved the way for a new era in the treatment of chronic skin diseases. This anticipated merger aims to harness Oruka's innovative portfolio of novel biologics to redefine the standard of care for patients suffering from these debilitating conditions. This article delves into the...

Product Service News

Biomerica's InFoods IBS Technology to be Showcased at the Prestigious DDW Annual Meeting

Biomerica, Inc., an esteemed global biomedical company specializing in innovative gastroenterology solutions, has proudly announced that its groundbreaking inFoods IBS technologies will be featured in the IBS Clinical Session at the 2024 Digestive Disease Week (DDW) Annual Meeting in Washington DC. This prestigious event is renowned as the leading scienti...

Volitionrx Limited

Volitionrx Limited Reports Significant Loss Despite Revenue Increase

Volitionrx Limited's recent financial results give cause for concern and indicate a bearish outlook for the company. Despite reporting a strong revenue increase of 103.795% year-on-year, reaching $0.24 million, the company still suffered a significant loss of $-0.12. This suggests that the company's expenses may be outpacing its revenue growth, raising do...


About us


CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com